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Introduction
 
The metabolic syndrome, characterized by abdominal obesity,
hyperglycaemia, hypertension and dyslipidaemia, confers a
high risk of the development of Type 2 diabetes mellitus (DM2)
[1,2] and cardiovascular disease (CVD) [3]. The prevalence of
elevated liver enzymes, including alanine aminotransferase
(ALT), is higher in individuals with DM2 or the metabolic syn-
drome [4,5]. Several cross-sectional studies have demonstrated
associations of ALT with individual components of the metabolic
syndrome, including obesity and dyslipidaemia [6,7]. To date,
a limited number of studies have addressed the prospective
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Abstract
 
Aims
 
To study the association between alanine aminotransferase (ALT) and
the 6-year risk of the metabolic syndrome in a population-based study in Caucasian
men and women.
 
Methods
 
The association of ALT with the 6-year risk of the metabolic syndrome
in 1097 subjects, aged 50–75 years, was assessed in the Hoorn Study with logistic
regression analysis. Subjects with the metabolic syndrome at baseline, defined
according to the Adult Treatment Panel III of the National Cholesterol Education
Program, were excluded.
 
Results
 
After 6.4 (range 4.4–8.1) years follow-up, 226 subjects (20.6%) had
developed the metabolic syndrome. The odds ratio (95% confidence interval)
for developing the metabolic syndrome, adjusted for age, sex, alcohol intake
and follow-up duration was 2.25 (1.50–3.37) for subjects in the upper tertile
compared with those in the lower tertile of ALT. This association persisted after
additional adjustment for all the baseline metabolic syndrome features [1.62
(1.02–2.58)]. Among the individual components of the metabolic syndrome,
ALT was significantly associated only with fasting plasma glucose at follow-up.
 
Conclusions
 
These data suggest that ALT is associated with risk of the meta-
bolic syndrome in a general population of middle-aged Caucasian men and
women, further strengthening the role of ALT as an indicator for future meta-
bolic derangement. These findings warrant further studies to elucidate the role
of non-adipose tissue fat accumulation in the pathogenesis of complications
related to the metabolic syndrome.
Diabet. Med. 24, 430–435 (2007)
 
Keywords
 
metabolic syndrome, alanine aminotransferase, epidemiology, elderly 
 
Abbreviations
 
ALT, alanine aminotransferase; CI, confidence interval; CRP,
C-reactive protein; DM2, Type 2 diabetes mellitus; HDL, high-density lipoprotein;
OR, odds ratio
 
Blackwell Publishing LtdOxford, UKDMEi betic Medic ne0742-3071 , 200724Epid miologyA nine aminotransferase and metabolic syndrome 
 
R. K. Schindhelm et al.
Alanine aminotransferase and the 6-year risk of the 
metabolic syndrome in Caucasian men and women: 
the Hoorn Study
 
R. K. Schindhelm*, J. M. Dekker†, G. Nijpels†‡, C. D. A. Stehouwer§, L. M. Bouter†, 
R. J. Heine*† and M. Diamant*
 
*Department of Endocrinology/Diabetes Centre, 
†EMGO Institute, ‡Department of General Practice, 
VU University Medical Centre, Amsterdam and 
§Department of Internal Medicine, Academic 
Hospital Maastricht, Maastricht, the Netherlands 
 
Accepted 29 November 2006
 
dme_2100.fm  Page 430  Monday, March 19, 2007  5:00 PM
 © 2007 The Authors.
Journal compilation © 2007 Diabetes UK. 
 
Diabetic Medicine
 
, 
 
24
 
, 430–435
 
431
 
Epidemiology
 
DIABETIC
 
Medicine
 
relation of liver enzymes with the future risk of the metabolic
syndrome. Nakanishi 
 
et al
 
. found that, of the liver enzymes
studied, ALT was associated with risk of metabolic syndrome,
but this study was limited to middle-aged Japanese men and
used body mass index instead of waist circumference to define
the metabolic syndrome [8]. Hanley 
 
et al
 
. studied the relation
of four different liver enzymes (including ALT) with the devel-
opment of the metabolic syndrome in a multi-ethnic cohort
and demonstrated that ALT was positively associated with
risk of the metabolic syndrome [9]. In a Japanese cohort of
male and female health-care employees, Suzuki 
 
et al
 
. studied
the sequential order of elevated transaminases (ALT and
aspartate aminotransferase) with features of the metabolic
syndrome, and found that elevated transaminases are pre-
ceded by weight gain, while the other features are followed by
elevated transaminases [10]. To date, no study has assessed the
prospective relationship of ALT and the metabolic syndrome
in a population-based study in Caucasian men and women.
In the present study, we addressed the prospective association
of ALT with the 6-year risk of the metabolic syndrome,
defined according to the Adult Treatment Panel III of the
National Cholesterol Education Program, and with the indi-
vidual components of the metabolic syndrome in a population-
based study of glucose tolerance and related complications in
Caucasian men and women aged 50–75 years at baseline.
 
Subjects and methods
 
Subjects and follow-up
 
The subjects were participants in the Hoorn Study, a prospec-
tive population-based cohort study of glucose metabolism and
diabetes complications [11]. Briefly, in 1989, a random sample
of all man and women aged 50 to 75 years was taken from the
municipal registry of the town of Hoorn in the Netherlands. Of
the 3552 individuals who were invited to take part in the study,
2540 agreed to participate (71%). Baseline data were collected
from October 1989 to February 1992. After excluding non-
Caucasians (
 
n
 
 = 56), the study cohort consisted of 2484 men
and women. Between January 1996 and December 1998, 2086
participants were invited to take part in a follow-up examination;
the other members of the original study population were not
invited for logistical reasons (
 
n
 
 = 140), or because they had died
(
 
n
 
 = 150) or had moved out of Hoorn (
 
n
 
 = 108). In total, 1513
subjects (72.5%) took part in the follow-up measurements
[12]. Metabolic syndrome at baseline and at follow-up was
defined according to the Adult Treatment Panel III of the
National Cholesterol Education Program, i.e. three or more of
the following: fasting glucose 
 
≥
 
 6.1 mmol/l, high-density lipo-
protein (HDL) cholesterol < 1.0 mmol/l (men) or < 1.3 mmol/l
(women), triglycerides 
 
≥
 
 1.7 mmol/l, waist circumference 
 
≥
 
 102 cm
(men) or 
 
≥
 
 88 cm (women) and hypertension 
 
≥
 
 130/85 mmHg
[13]. For the present study, subjects with the metabolic syndrome
and/or DM2 at baseline were excluded (
 
n
 
 = 329). Furthermore,
subjects with missing data on alcohol intake, missing data on
ALT enzyme activity, insulin, smoking status and physical activity
at baseline were also excluded (
 
n
 
 = 22). Finally, subjects with
missing data to define the metabolic syndrome at follow-up
(
 
n
 
 = 63) and subjects with ALT levels > 2.5 times the upper level
of the reference value (
 
n
 
 = 2) were also excluded, the latter to
reduce confounding as a result of subjects with ALT elevation
caused by viral or toxic agents. Thus, this analysis includes
1097 subjects. The Ethical Review Committee of VU University
Medical Centre approved the Hoorn Study and written in-
formed consent was obtained from all participants.
 
Methods
 
Measurements
 
Fasting blood samples were collected after an overnight fast
from 20.00 h the evening before. Serum ALT enzyme activity
was measured according to the 1985 method of the International
Federation of Clinical Chemistry [14]. Glucose was measured
in plasma with the glucose dehydrogenase method (Merck,
Darmstadt, Germany) at the baseline measurement and with
the hexokinase method (Boehringer, Mannheim, Germany) at the
follow-up measurement. Immuno-specific insulin was measured
in serum with a double-antibody RIA (antibody SP21; Linco
Research, St Louis, MO, USA). Triglycerides, total and HDL
cholesterol were determined in serum by enzymatic techniques
(Boehringer, Mannheim, Germany). Systolic and diastolic blood
pressure was measured twice on the right arm with a random-
zero sphygmomanometer (Hawksley-Gelman, Lancing, UK)
and the mean of both measurements used for the analyses.
Information on alcohol intake was assessed by a validated
semiquantitative food frequency questionnaire [15]. Subjects
were asked if they drink alcohol and, if so, how many glasses
they consume in a week. This information was converted to
alcohol intake in g/day with the computerized version of the
Dutch Food Composition Table. Physical activity was assessed
as described previously [11]. Weight and height were measured
in subjects wearing light clothes only, and the body mass index
was calculated as weight divided by height squared (kg/m
 
2
 
).
Waist and hip circumference were measured according to a
standardized method [16]. Smoking status was assessed by
questionnaire.
 
Statistical analysis
 
Data are presented as mean (
 
SD
 
) or as median (interquartile
range) for variables with a skewed distribution according to
tertiles of ALT. For the prospective data, logistic regression
analyses were performed to calculate the odds ratios (ORs) and
the 95% confidence intervals (CIs) for the metabolic syndrome.
The upper tertile of ALT was compared with the lower tertiles
of ALT. The first model was adjusted for age, sex, alcohol intake
and follow-up duration, because follow-up differed between
subjects. In the final model, additional adjustments were made
for the individual components of the metabolic syndrome crite-
ria entered as continuous variables. To assess the prospective
relation of ALT with the individual components of the metabolic
syndrome, we used multivariate linear regression models. In
these models, the individual metabolic syndrome component at
follow-up was entered as the outcome variable and ALT as the
determinant. These models were adjusted for age, sex and follow-
up duration and subsequently adjusted for the metabolic syndrome
component at baseline. These associations were expressed as
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standardized betas with the 95% CI. A standardized beta of 0.5
means that, if the independent variable increases by 1 
 
SD
 
, the
dependent variable increases by 0.5 
 
SD
 
. Variables with a skewed
distribution were entered in the models after logarithmic trans-
formation. The statistical analyses were performed with SPSS
for Windows version 11.0.5 (SPSS Inc., Chicago, IL, USA). A
two-sided 
 
P
 
-value < 0.05 was considered to indicate statistical
significance. Effect modification by age and sex were tested by
entering interaction terms (age times ALT tertile or sex times
ALT tertile) into the models. We choose a two-sided 
 
P
 
-value
< 0.1 to indicate effect modification.
 
Results
 
Baseline characteristics
 
The mean age of the 1097 participants (465 men and 632
women) was 60.0 years (
 
SD
 
 6.7). Table 1 shows the baseline
characteristics of the participants stratified by ALT divided
into tertiles. Subjects in the upper tertile were younger, more
likely to be male, had higher fasting glucose and cholesterol
levels, lower HDL cholesterol levels and a higher blood pressure,
compared with those in the lower tertile. The difference in fasting
triglyceride levels was not statistically significant.
 
Risk for development of the metabolic syndrome
 
Table 2 shows the OR of development of the metabolic
syndrome in 1097 men and women who were free of the meta-
bolic syndrome at baseline after a mean of 6.4 (range 4.4–8.1)
years of follow-up with ALT divided into tertiles. Of these, 226
(20.6%) subjects developed metabolic syndrome at follow-up.
In the model adjusted for age, sex and follow-up duration
and alcohol intake, subjects in the upper tertile had an OR of
2.25 (95% CI 1.50–3.37) compared with those in the lower
tertile. The subsequent models in which components of the
metabolic syndrome were entered as continuous variables
showed that this relation was most strongly attenuated by waist,
followed by glucose and to a lesser extent by blood pressure,
but the associations remained statistically significant [OR 1.62
(1.02–2.58)]. Lifestyle factors, including physical activity and
smoking, and fasting insulin did not affect the relationship to
a significant extent. No effect modification for sex or age was
observed (both 
 
P
 
 > 0.1). To further address the effect of alcohol
intake as a major potential confounder, we excluded subjects
(
 
n
 
 = 152) with an alcohol intake of more than 20 g per day.
However, this only led to a small attenuation of model 1 [2.10
(1.36–2.54)].
The models in which the components of the metabolic syn-
drome were entered as dichotomised variables (according to
the Adult Treatment Panel III of the National Cholesterol
Education Program) did not materially change the associations
presented in Model 1 (data not shown); the OR of Model 2
was slightly higher [OR 2.02 (1.31–3.12)].
The analyses assessing the relation of ALT with the individual
components of the metabolic syndrome showed that ALT was
associated with all the components at follow-up except for
HDL cholesterol. After adjustment for the baseline values of
the individual components, ALT was significantly associated
with glucose only (Table 3).
 
Discussion
 
The main finding of this study is that, in an elderly population
of non-diabetic Caucasian men and women free of the meta-
bolic syndrome at baseline, higher ALT was associated with an
increased risk of conversion to the metabolic syndrome. This
Table 1 Baseline characteristics of the participants (n = 1097) stratified by ALT tertiles
Variables
Alanine aminotransferase activity (U/l) 
Tertile 1 Tertile 2 Tertile 3 Ptrend*
n 329 418 350
ALT (U/l) 10.4 ± 2.1 15.6 ± 1.5 27.3 ± 10.1
Age (years) 60.9 ± 6.9 60.4 ± 6.8 58.6 ± 6.3 <0.001
Male (%) 27.1 41.9 57.4 <0.001
Body mass index (kg/m2) 25.2 ± 2.9 25.5 ± 2.7 26.6 ± 3.0 <0.001
Waist (cm) 84.5 ± 9.5 87.4 ± 8.7 91.0 ± 8.8 <0.001
Fasting glucose (mmol/l) 5.2 ± 0.5 5.3 ± 0.5 5.4 ± 0.5 <0.001
Plasma lipids (mmol/l)
Total cholesterol 6.5 ± 1.1 6.5 ± 1.0 6.6 ± 1.1 0.016
HDL cholesterol 1.42 ± 0.35 1.41 ± 0.36 1.38 ± 0.39 0.020
Triglycerides 1.2 (0.9–1.5) 1.2 (0.9–1.5) 1.3 (1.0–1.6) 0.054
Systolic BP (mmHg)  127 ± 18  130 ± 17  131 ± 18 <0.001
Diastolic BP (mmHg)  78 ± 10  79 ± 9  82 ± 9 <0.001
ALT, alanine aminotransferase; BP, blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
Data are means ± SD or median (interquartile range) for variables with a skewed distribution.
*Tested for trend with regression analyses adjusted for age and sex.
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association was independent of age, sex, alcohol intake, follow-
up duration and the baseline metabolic syndrome components.
In the prospective analyses of the individual components of the
metabolic syndrome, ALT was significantly associated with
fasting glucose levels and to a lesser extent with HDL choles-
terol, triglyceride levels and elevated blood pressure and waist
circumference.
The findings of the present study are in accordance with the
two previous studies, predominantly performed in Asian [8]
and African-American and Hispanic [9] populations, that
addressed the relation of liver enzymes including ALT with
future risk of the metabolic syndrome. Correction of all the
baseline metabolic syndrome criteria may result in over-
correction, implying that the models in the present study may
underestimate the true associations. Other risk factors for the
development of the metabolic syndrome have been studied.
These factors included C-reactive protein (CRP) [17], physical
inactivity [18], pro-insulin [19] and the individual components
themselves [19]. In the present study, physical activity did not
affect the associations. Unfortunately, pro-insulin and CRP
levels were not available at baseline in the Hoorn study cohort
and consequently the effect of these mediating or confounding
variables could not be studied.
The chronological ordering of elevated transaminases (ALT
and aspartate aminotransferase) in relation to components of
the metabolic syndrome was studied by Suzuki 
 
et al
 
.; they
reported that weight gain, low HDL cholesterol and hypertrig-
lyceridaemia preceded transaminase elevation, and that hyper-
tension and glucose intolerance then followed [10]. Our study
was not designed to study the chronological ordering of ALT
with the individual components of the metabolic syndrome;
however, our results do support some of the findings by Suzuki
 
et al
 
.—that elevated ALT precedes components of the metabolic
syndrome. Indeed, glucose at follow-up, adjusted for baseline
glucose values, was the strongest component associated with
elevated ALT.
The mechanisms underlying the observed association between
ALT (and other liver enzymes) and the metabolic syndrome
are not yet fully understood. ALT is most strongly associated
with liver fat accumulation measured by proton magnetic
Metabolic syndrome component at follow-up
Standardized betas (95% CI) 
Model 1 Model 2
Fasting glucose 0.19 (0.13; 0.25) 0.13 (0.07; 0.18)
Waist circumference 0.17 (0.11; 0.22) 0.004 (−0.03; 0.04)
Triglycerides 0.10 (0.03; 0.16) 0.05 (−0.001; 0.10)
Diastolic blood pressure 0.10 (0.04; 0.17) 0.03 (−0.02; 0.09)
Systolic blood pressure 0.09 (0.03; 0; 15) 0.03 (−0.02; 0.08)
HDL cholesterol 0.03 (−0.03; 0.09) −0.02 (−0.05; 0.02)
Models 1 and 2 adjusted for age, sex, alcohol intake and follow-up duration.
Model 2 additionally adjusted for the baseline value of the individual component.
*Standardized betas indicate SD difference per 1 SD ALT at baseline.
Models*
n
ALT enzyme activity
Tertile 1 
329
Tertile 2 
418
Tertile 3 
350
Model 1 1 1.43 (0.96–2.13) 2.25 (1.50–3.37)
Model 1 + waist 1 1.30 (0.89–1.95) 1.70 (1.11–2.58)
Model 1 + glucose 1 1.34 (0.89–2.01) 2.01 (1.33–3.03)
Model 1 + HDL cholesterol 1 1.55 (1.03–2.32) 2.60 (1.72–3.95)
Model 1 + triglycerides 1 1.54 (1.03–2.35) 2.18 (1.43–3.33)
Model 1 + systolic BP 1 1.39 (0.93–2.08) 2.08 (1.38–3.14)
Model 1 + diastolic BP 1 1.41 (0.95–2.10) 2.11 (1.40–3.18)
Model 1 + lifestyle factors† 1 1.45 (0.97–2.18) 2.29 (1.51–3.48)
Model 1 + insulin 1 1.46 (0.97–2.20) 2.19 (1.44–3.35)
Model 2 1 1.40 (0.90–2.18) 1.62 (1.02–2.58)
*Model 1 adjusted for age, sex, alcohol intake and follow-up duration; Model 2, 
Model 1 + adjusted for waist, glucose, high-density lipoprotein (HDL) cholesterol, 
triglycerides and systolic and diastolic blood pressure (BP).
†Lifestyle factors: smoking and physical activity.
Table 2 The associations of ALT with 
development of the metabolic syndrome 
(n = 1097)
Table 3 Multivariate linear regression 
analysis of ALT with the individual metabolic 
syndrome components at follow-up*
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resonance spectroscopy [20], reflecting fat deposition in the
liver, which is regarded as a feature of the metabolic syndrome
[21,22]. This hepatic fat deposition, as reflected by slightly
elevated ALT levels, may lead to early hepatic and systemic
insulin resistance [23,24]. Indeed, an earlier study demon-
strated that hepatic fat content measured by proton spectros-
copy is associated with insulin resistance, independent of
obesity [25]. In addition, hepatic fat content was related to
decreased suppression of insulin-mediated hepatic glucose
output, which is in line with the observation of the present
study that ALT is positively associated with fasting glucose
levels in the prospective analysis. High ALT levels might also
reflect hepatic and systemic inflammation, and the interplay of
visceral adipose tissue, stimulating hepatic CRP production which
may contribute to further metabolic derangement. The results
of the present study show that subjects with slightly elevated
ALT have a higher risk of developing the metabolic syndrome.
A number of potential limitations of this study should be
considered. The population consisted of Caucasian individuals
aged 50–75 years, and caution should be exercised in generaliz-
ing our findings to other populations. Although we controlled
for alcohol as a confounder in our study, we could not account
for other factors that might have caused a rise in ALT, such as
viral hepatitis infections or hepatotoxic drugs. To overcome
this limitation to some extend, subjects with an ALT level of
2.5 times the upper level of the reference value were excluded.
In approximately one-third of hepatitis C infections, a condition
associated with an increased risk for development of diabetes,
subjects may have normal ALT levels [26,27]. However, the
effect of hepatitis C on our results may be very limited, as
the prevalence of hepatitis C infection in the Dutch general
population is very low [28]. In addition, the association of
other liver enzymes such as asparatate aminotransferase and
 
γ
 
-glutamyltransferase with risk of developing the metabolic
syndrome was not assessed. A previous study, however, found
that ALT was the enzyme most strongly correlated to hepatic
fat accumulation [20]. In the Hoorn study, no investigations
were performed to assess the cause of elevated ALT. However,
all relevant baseline data was send to the individual’s general
practitioner, with advice to perform further tests according to
prevailing guidelines.
Despite these limitations, the findings obtained in a population-
based study of elderly Caucasian men and women support the
conclusion that ALT is positively associated with the meta-
bolic syndrome and further studies are needed to elucidate and
understand the pathophysiological mechanisms.
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